T Turi

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo et al. · Journal of the American College of Cardiology · 2021 · 141 citations · Full text

Medicine, Cardiology, Pharmacology +17

Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome

Gorav Batra, Tatevik Ghukasyan Lakic, Johan Lindbäck et al. · JAMA Cardiology · 2021 · 111 citations · Full text

Medicine, Cardiology, Immunology +15

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

Gregory G. Schwartz, Michael Szarek, Vera Bittner et al. · Diabetes Care · 2021 · 38 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

The natural history of postischemic T-wave inversion: a predictor of poor short-term prognosis?

Krzysztof Simon, D. Hackett, A Szelier et al. · PubMed · 1994 · 11 citations

Medicine, Cardiology, Internal Medicine +13